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Abstract
Background: Malnutrition is reported in pediatric neu-
romotor disability and impacts the child’s health. We 
described the nutritional and metabolic status in neuro-
logically impaired (NI) children undergoing surgery.
Methods: Anthropometry, body composition, hormonal 
and nutritional evaluations were performed in 44 NI sub-
jects (13.7 ± 8.0  years). Energy needs were calculated by 
Krick’s formula. Metabolic syndrome (MS) was defined 
applying the following criteria ( ≥  3 defined MS): fasting 
blood glucose > 100  mg/dL and/or homeostasis model 
assessment for insulin resistance (HOMA-IR) > 97.5th 
percentile, trygliceride level > 95th percentile, high-
density lipoprotein (HDL)-cholesterol level < 5th percen-
tile, systolic/diastolic pressure > 95th percentile; while-
body mass index – standard deviation score (BMI-SDS) 
< 2 and biochemical malnutrition markers ( ≥  2) defined 
undernutrition.
Results: Energy intake was not adequate in 73.8% of the 
patients; no correlation between energy intake and BMI 
was noted. Undernutrition was noted in 34.1% of patients 
and MS in 11.36% of subjects. Fifty percent of the patients 
presented with insulin resistance, which was not related 
to BMI, body composition or other MS components.
Conclusions: Nutritional and metabolic monitoring of 
disabled children and young adults is recommended to 
prevent adverse outcomes associated with malnutrition.
Keywords: children; disabilities; metabolic syndrome; 
nutrition; pediatric surgery.
Introduction
Malnutrition is one of the primary contributing factors in 
poor health status [1–3]. Poor nutrition negatively affects 
growth in children as well as negatively impacts body 
composition, muscle strength, the metabolic/endocrine 
profile, cardiovascular and respiratory systems, immune 
function, wound healing and surgical outcomes. Mal-
nutrition, in general, is the best-studied contributor to 
poor growth in children [4, 5] and its high incidence and 
prevalence in neurologically impaired (NI) children [6, 7] 
may enhance poorer health and development, leading to 
a perpetuating cycle of sub-optimal nutrition, disability 
and worsening conditions [8]. The cause of malnutrition 
in these patients is multifactorial, including inappropriate 
dietary energy intake, oral motor dysfunction, increased 
nutrient losses, abnormal energy expenditure (EE) and 
physical exertion [9].
Nutritional support is essential for the care of NI 
children and nutritional rehabilitation improves overall 
health and quality of life for both patients and their fami-
lies [9, 10]. Children are especially vulnerable to inad-
equate nutrition support (NS) because of their smaller 
body size and lesser lean body and fat mass reserves [11]. 
Suboptimal nutrient provision contributes to nutritional 
status deterioration and has been shown to increase the 
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risk of multi-organ failure, length of hospital stays and 
mortality [11].
A full nutritional risk/benefit assessment should be 
carried out before gastrostomy tube (GT) placement. In 
addition, nutritional monitoring is essential to assess 
the adequacy of the initial nutritional prescription and 
to guide adjustments to the nutritional regimen [12] in 
order to ensure growth, counteract NI pediatric patient 
morbidity and mortality and minimize negative surgical 
outcomes in debilitated patients.
The primary aim of this study was to describe the 
nutritional and metabolic status in NI children followed 
at our pediatric surgical unit for nutritional gastrostomy/
digiunostomy tube positioning and surgical procedures 
such as anti-reflux-surgery or management of nutritional 
support devices. Increased knowledge and awareness of 
nutritional screening among all health care professionals 
involved in surgical procedures is an essential objective 
to improve outcomes in children with severe disabilities 
undergoing surgery.
Subjects and methods
Subjects
Forty-four patients (25 males, 19 females, mean age 13.7 ± 8.0) with 
severe disabilities, scheduled for surgical gastrostomy/digiunostomy 
tube positioning, anti-reflux surgical treatment and/or manage-
ment of nutritional support devices were included in the study. The 
patients were enrolled between February 01, 2016 and May 01, 2016.
Patient diagnoses included: cerebral palsy (CP) (38.6%), epilep-
tic encephalopathy (34.1%), severe psycomotor developmental delay 
in dysmorphic syndromes (27.3%). All patients, living either at home 
or in sheltered community accommodations, presented with neuro-
motor damage that could alter their ability to self-feed and were 
 bedridden.
The study was performed according to the Declaration of Helsinki 
and with the approval of the Institutional Review Board. After hav-
ing received information about the nature of the study, the patient’s 
parents or tutors gave written consent for their child’s participation.
Methods
Anamnestic investigation, clinical evaluation, anthropometric meas-
urements, body composition estimation, nutritional assessment, bio-
chemical and endocrinological profile were performed in all patients.
Anamnestic investigation, clinical and anthropometric para-
meters: A medical history was collected including a recall of the 
underlying disease, gestational and birth data, chronical use of 
medications; furthermore, the number of physiotherapy treatment 
sessions was recorded.
Physical examination of the patients included anthropometric 
measurement of weight, height, body segments, mid upper arm cir-
cumference (MUAC), as well as pubertal stage evaluation according 
to Marshall and Tanner [13, 14] (prepubertal characteristics corre-
sponding to Tanner stage 1) and blood pressure measurement.
To record the weight measurement, the child was first weighed 
while being held by his/her parent or legal caregiver, next the par-
ent or legal caregiver was weighed, and subsequently, the difference 
between both weights was obtained. Weight measurement was made 
using a platform-type balance (Wunder San 200A, Bergamo, Italy).
To obtain reliable measurements of height and length, anthro-
pometry was performed measuring body segment lengths according 
to Stevenson’s method [15]. Total length of the tibia was obtained by 
measuring the straight distance from the cranial articular surface to 
the fibular condyle of the tibia, i.e. lateral condyle to the tip of the 
medial malleolus. Ulna length was measured from the tip of the olec-
ranon process to the tip of the styloid process. Data corresponding to 
the average of the ulna measurements and tibia lengths were used 
to obtain an estimate of stature according to specific equations [15].
Body mass index (BMI) was calculated by dividing the patient’s 
weight in kilograms by the square of the height in meters. MUAC was 
measured at the mid-point between the tip of the shoulder and the tip 
of the elbow (olecranon process and the acromium), using a standard 
measuring tape.
Systolic (SBP) and diastolic (DBP) blood pressure readings were 
taken twice using a mercury sphygmomanometer, after the partici-
pant sat comfortably for 5 min, with an appropriately sized cuff on 
the right arm, which was slightly flexed at heart level. The second BP 
measurement was used for the analysis.
Body composition: Body composition was estimated by bioelec-
trical impedance (BIA-101  model; Akern, Florence, Italy), using an 
alternating electric current at low intensity (800 μA) and fixed rate 
frequency at 50 kHz.
As previously described [16, 17], measurements were assessed 
on the non-dominant side of the body between the ipsilateral wrist 
and ankle bony prominences. The two electrodes were placed on the 
skin, previously cleaned with alcohol, 5 cm apart from each other. 
The two distal current-introducing electrodes were placed on the 
dorsal surfaces of the hand and foot proximal to the metacarpal 
phalangeal and metatarsal phalangeal joints, respectively. The two 
voltage-sensing electrodes were applied at the pisiform prominence 
of the wrist and between the medial and lateral malleoli of the ankle. 
The patient was placed in a horizontal position for 10 min, in order to 
allow a homogeneous distribution of body fluids, avoiding any con-
tact that could short-circuit the electrical current pathway; the arms 
and the legs were abducted at a 30- to 45-degree angle from the trunk. 
The measurements were taken with the child as relaxed as possible, 
taking about 1 min in total.
Resistance, reactance and phase angle were registered. Total 
body water, fat-free mass and fat mass percentage, were afterward 
estimated using the manufacturer’s BIA estimation equations 
[18, 19].
Nutritional assessment: Nutritional support mode access (pump 
versus bolus) and feeding regime were recorded. All children were on 
enteral nutritional support and were divided into three categories: 
oral nutrition, continuous enteral feeding and bolus enteral feeding.
Nutrient intake was determined with a 24-h recall question-
aire administered to the child’s parents by a trained dietician, as 
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previously described [20]. We also registered the kind and quantity of 
formula, number of meals (for oral nutrition and bolus enteral feed-
ing), timing and length of each meal.
Energy intake was estimated from the 24-h recall data and then 
compared with the CP-specific equation by Krick et al. [21] that esti-
mates the total EE calculating basal metabolic rate (BMR) according 
to Fleisch [22], modified for muscle tone, activity and normal growth.
Biochemical and endocrinological parameters: Blood indicators of 
malnutrition included the following blood chemistry investigations: 
hemoglobin, hematocrit, mean corpuscolar volume, platelet count, 
serum iron, ferritin, prealbumin, calcium, vitamin D, folate, vitamin 
B12, leptin, IGF1 and IGFBP3 blood levels. The subjects were defined 
as undernourished if they met BMI-SDS < 2 and at least  ≥  2 patho-
logical values of the biochemical markers of malnutrition according 
to age and sex [23]. Metabolic and hormonal blood assays included 
fasting blood glucose (FBG), insulin, total cholesterol, high-density 
lipoprotein (HDL) cholesterol, triglycerides (TG), Glutamic Oxal-
acetic Transaminase (GOT), glutamate pyruvate transaminase (GPT), 
Gamma-glutamyl transpeptidase (GGT), free T4 (FT4) and thyroid 
stimulating hormone (TSH). Insulin resistance was calculated by 
homeostasis model assessment for insulin resistance (HOMA-IR) [24].
Abnormalities in lipid-fasting levels were considered for TG val-
ues exceeding the 95th percentile and HDL cholesterol values below 
the 5th percentile for age and sex [25]. Impaired insulin sensitivity 
(ISI) was defined with HOMA-IR that exceeded the 97.5th percentile 
for age and sex [26, 27]. Elevated SBP or DBP was defined with values 
exceeding the 95th percentile for age and sex [28].
Patients were considered as having the MS if they met more than 
three of the following criteria for age and sex: FBG > 100 mg/dL and/
or HOMA-IR > 97.5th percentile, TG level > 95th percentile, HDL cho-
lesterol level < 5th percentile, SBP and/or DBP > 95th percentile.
On the basis of gestational age and birth weight, children were 
defined appropriate for gestational age with a birth weight  ≥  10th 
percentile and small for gestational age with a birth weight < 10th 
percentile [29, 30].
Statistical analysis
All analyses were performed using Stata 14 (StataCorp, College Sta-
tion, TX, USA). Data were described with the mean, standard deviation 
(SD), median and 25th–75th percentiles if continuous and as counts 
and percent if categorical. Non parametric correlations between con-
tinuous variables were assessed with the Spearman’s R test. The asso-
ciation of categorical variables was assessed with the Fisher’s exact 
test. For the purpose of this analysis, biomarkers were dichotomized 
at the local laboratory cut-off for normality. All tests were two-sided. 
A p-value < 0.05 was considered statistically significant.
Results
Clinical characteristics
In Table 1, the clinical features and anthropometric para-
meters of the patients are reported. Ta
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The patients were divided into groups according 
to their nutritional status (normal nutrition or under-
nutrition) and data were assessed descriptively and 
comparatively.
Nutritional support mode access and feeding regime 
of the enrolled subjects were:
 – continuous enteral feeding in ten subjects (23.3%) 
and bolus enteral feeding in 27 (62.8%), with nasogas-
tric tube in nine patients (20.45%) and gastrostomy in 
30 (68.2%);
 – oral nutrition (4–6  meals/day) in five subjects 
(11.4%).
Anticonvulsive drugs (at least two of the following: phe-
nobarbital, valproic acid, phentoyn, lamotrigine, topira-
mate, carbamazepine and clonazepam) were reported in 
39/44 (88.6%) of the whole sample.
Birth weight was appropriate in 87.1% and small in 
12.90% of the cases.
Pubertal stage was Tanner 1 in 15 patients (34.9%), 
Tanner stage 2–3 in six (13.9%. Two of these, 33%, were 
aged < 8 years) and Tanner stage 4–5 in 22 (51.2%).
At evaluation, BMI was < − 2 SDS in 47.7% of the sub-
jects; in 29.5% of these, BMI was < − 3 SDS. A high corre-
lation between BMI and MUAC was observed (p < 0.001, 
Spearman’s R = 0.66).
One overweight child was detected but no children 
with obesity were detected.
Respiratory physiotherapy was recorded in 95% of 
the cases; the frequency of the sessions was < 2 h/week/
month for all of the patients. No ongoing physical therapy 
was reported.
Body composition and indicators 
of  nutritional status
Table 2 shows the body composition and indicators of the 
patients’ nutritional status.
According to the values of energy needs estimated 
using Krick’s formula, it emerged that the patient’s daily 
energy intake was not adequate in 73.8% of the patients; 
it was lower than expected in 23.8% of the subjects and 
higher in 50%. No correlation between energy intake and 
BMI was noted as in Table 3.
We observed extremely low phase angles (3.33 ± 0.86); 
however, the phase angle was not significantly correlated 
to daily energy intake, or to the blood indicators of mal-
nutrition such as IGF1, IGFBP3, prealbumin, or to the 
auxological parameters such as BMI, MUAC as can be seen 
from Table 3. Ta
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Blood indicators of malnutrition
Blood level malnutrition biomarkers are reported in 
Table 4. Overall, undernutrition occurred in 34.1% (95% 
CI 20–49%) of the whole sample: 40% males (95% CI 
21 to − 61%) and 26.32% females (95% CI 9 to − 51%). 
In Tables  1, 2, 4 and 6, clinical data, body composition 
and values of nutritional, metabolic and hormonal para-
meters in normal nutrition and undernutrition groups are 
reported.
As reported in Table  5, no association between 
undernutrition and gender (p = 0.5) or type of nutritional 
support was observed (p = 0.09).
The prevalence of each nutritional alteration is 
reported in Figure  1. All the patients with high levels of 
vitamin B12 and folate were receiving anticonvulsivant 
drugs; no association between B12/folate abnormalities 
and liver abnormalities or feeding method was noted 
(p = 0.8).
Table 3: Relevance of correlations among body composition, 
 nutritional and metabolic markers.
  Spearman’s R  p-Value
Phase angle  
 Energy intake, kcal   0.15  0.34
 IGF, ng/mL   0.08  0.60
 IGFB3, ng/mL   − 0.09  0.60
 Prealbumin, mg/dL   0.32  0.06
 Leptin, pg/mL   0.03  0.84
 BMI, kg/m2   − 0.04  0.79
 MUAC, cm   0.03  0.80
Prealbumin, mg/dL  
 Energy intake   0.37  0.019
 IGF, ng/mL   0.39  0.011
 IGFB3, ng/mL   0.34  0.028
 MUAC, cm   0.30  0.055
Leptin, pg/mL  
 IGFB3, ng/mL   0.33  0.037
 MUAC, cm   0.70  <0.001
 BMI, kg/m2   0.33  <0.001
 FM, %   0.62  <0.001
 FFM, %   − 0.63  <0.001
HOMA-IR  
 BMI, kg/m2   0.12  0.45
 FM, %   0.15  0.40
 FFM, %   − 0.16  0.35
 Total cholesterol, mg/dL  − 0.19  0.23
 HDL-cholesterol, mg/dL   0.33  − 0.15
 Tryglicerydes, mg/dL   0.21  0.17
 Blood pressure, mmHg   0.11  0.50
Tryglicerides, mg/dL  
 Leptin, pg/mL   0.45  0.003
 FM, %   0.45  0.009
 FFM, %   − 0.44  0.010
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A significant correlation between prealbumin levels 
and energy intake, IGF1, IGFBP3, MUAC was reported 
(Table 3).
Leptin values were significantly related to IGFBP3, 
MUAC, BMI, FFM, FM (Table 3).
Vitamin D is far from the optimal level (30–50 nmol/L) 
in almost all the samples (84%): 50% of the subjects show 
levels of deficiency, despite the standard supplementa-
tion they received with enteral nutrition.
Metabolic and hormonal parameters
Metabolic and hormonal laboratory data are summarized 
in Table 6. Overall, MS occurred in 11.36% (95% CI 3–24%) 
of patients, in particular 8% of males (95%CI 0.926%) and 
15.8% of females (95% CI 3–39%).
The prevalence of each MS component is described in 
Figure 2.
Table 5: Prevalence of undernutrition according to gender, weight 
at birth and nutritional support.
Variables  
 
Undernutrition  p-Value
No  Yes
Gender      
 Males   15 (60%)  10 (40%)  0.5
 Females   14 (73.7%)  5 (26.3%) 
Weight at birth      
 AGA   16 (59.26%)  11 (40.74%)  1.0
 SGA   3 (75%)  1 (25%) 
Nutritional support      
 Enteral continuous  7 (70%)  3 (30%)  0.09
 Enteral bolus   20 (74.1%)  7 (25.9%) 
 Oral   1 (20%)  4 (80%) 
AGA, appropriate for gestational age; SGA, small for gestational age.
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Figure 1: Prevalence of biochemical markers of malnutrition.
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In summary, insulin resistance was reported in 50% of 
the patients presented with; this pathological parameter 
was not related to BMI, body composition or other indi-
cators of MS. The metabolic elements were not correlated 
to energy intake except for total cholesterol. A significant 
correlation between trygliceride values and leptin, fat 
mass as well as free fat mass was revealed as in Table 3.
Elevated transaminase levels were reported in 27.2% 
and central hypothyroidism was observed in 6.98% of the 
treated patients.
Discussion
This study confirmed that malnutrition is common in chil-
dren and young adults with NI and showed that a high 
prevalence of metabolic disorders is also relevant. The 
role of nutrition in maintaining health and well-being is 
crucial and optimal nutrition is a powerful predictor of 
survival in at-risk disabled populations [9].
Children and young adults with disabilities are 
particularly vulnerable to malnutrition. Inadequate 
nutritional status acts synergistically with endocrine 
dysfunction [31–33], and a variety of other factors, such 
as mechanical forces and neurological differences [31, 
34] affects the growth as well as the nervous system 
development and function [35–40], the digestive and 
immune system [41] and cardiovascular endurance [42, 
43], all of which influence the prognosis. In addition, 
malnutrition decreases the energy available for discre-
tionary activity, which in turn decreases social interac-
tion, increases apathy, and negatively affects learning 
and quality of life [44].
Nutritional support is a part of an integrated treat-
ment approach in NI subjects. Oral intake should be opti-
mized to ensure safe enteral tube feedings in patients with 
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Figure 2: Prevalence of metabolic syndrome criteria.
oromotor dysfunction or in children and young adults 
unable to maintain an adequate nutritional status only by 
oral intake [9, 45, 46]. Nevertheless, energy needs are dif-
ficult to define in this heterogeneous population, and NI 
children’s energy requirements (ER) are disease-specific 
differing according to disability severity, mobility impair-
ment, feeding difficulties, as well as the degree of altered 
metabolism [46, 47]. The results of this study confirm that 
in children with severe intellectual impairment, the nutri-
tional state is not primarily determined by energy intake 
[48]. Malnutrition also occurs in patients with an energy 
intake higher than expected. This lack of a direct relation-
ship between intake and nutritional status could reflect 
the modulating influence of inflammation, eventhough in 
some cases a “non plausible” parent’s reporting of energy 
intake should not be excluded.
Differences in EE presumably play an important role. 
The association between intake and physical function 
could be mediated by an increase of ER in these patients. 
Individualized nutritional care should be preferably based 
on EE measured by indirect calorimetry or estimated with 
specific target equations, in order to meet ER [47].
Repeat nutritional assessment is mandatory to adjust 
energy intake; and assessment of body composition 
changes is recommended, as it is a better indicator than 
weight for health status. In our population, bioelectrical 
parameters showed higher resistance and lower reactance 
values compared to normal weight young subjects [49, 
50] as well as extremely lower phase angles (3.33 ± 0.86). 
The parameter of phase angle (PA) in BIA is derived from 
the measurement of reactance and resistance, and is not 
conditioned by body weight or fat mass. Lower PA is asso-
ciated with loss of cell membrane integrity and worse 
prognosis [51, 52]. Severe malnutrition is common in NI 
children and young subjects with feeding difficulties and 
the PA changes as well as its modulation by IL-1β may 
reflect a reduction in muscle mass influenced by inflam-
mation [53]. However, it is difficult to draw conclusions 
about the change in body composition over time from a 
cross-sectional study because of confounding and selec-
tion factors and lead-time bias.
As far as nutritional biomarkers are concerned, 
vitamin D deserves meticulous attention. It is mainly 
needed for bone growth and bone remodeling [54, 55] but 
has other roles in the body, including modulation of cell 
growth, neuromuscular and immune function, and reduc-
tion of inflammation [54, 56, 57]. Serum concentration of 
25(OH)D is the best indicator of vitamin D status. In this 
sample, 50% of the subjects had values below 30 nmol/L 
that constitute a deficiency leading to rickets in children 
and osteopenia. Since the NI young patients are unlikely 
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to obtain adequate vitamin D from sunlight, intake of ade-
quate levels of vitamin D from foods and/or supplements 
is a critical issue. Health care providers should also be 
aware of potential interaction of vitamin D supplements 
with several types of medications (phenobarbital, pheni-
toyn, etc.) and therefore adjust supplement dose to indi-
vidual needs.
In the present study, low IGF1 and IGFBP3 levels were 
also detected. IGF-I is the primary mediator of growth 
hormone effects, and is thought to be the major IGF affect-
ing growth, health and disease following fetal develop-
ment [58–60]. Nutrition is one of the main regulators of 
circulating IGF-I [61] and our results confirmed this rela-
tionship in NI children and young patients. Leptin may 
very well be an integral signal which regulates neuroen-
docrine responses in times of food deprivation. According 
to the correlation between leptin and IGBP3, the role of 
leptin as a neuromodulator of the GRF-GH-IGF axis is sup-
ported [62–64].
To our knowledge, the metabolic risk in NI children 
and young adults has not been previously explored. We 
found a high prevalence of MS and insulin resistance (IR) 
in these undernourished subjects. MS is usually closely 
linked to an overweight status and obesity; this condition 
in normal weight subjects has already been described in 
the literature [65–71]. The effects of childhood malnutri-
tion on metabolic adult health are poorly understood. This 
is the first study to report a correlation between under-
nutrition, IR and metabolic disorders in the NI pediatric 
population.
Insulin resistance in our patients was not correlated to 
BMI or energy intake. Negative regulation of insulin sign-
aling could be viewed as a physiologic “adaptive mecha-
nism for human survival” that is activated whenever the 
organism needs to switch from an anabolic to a catabolic 
or “insulin resistance” state, such as undernutrition, 
and to mobilize energy, primarily in the form of glucose 
released from the liver and free fatty acids released from 
adipocytes, to support vital metabolic processes [72–74].
Chronic stress also tends to alter the anabolic/cata-
bolic hormonal balance and may be involved in metabolic 
disorders, hinder the development and function of skele-
tal muscle mass, increase cortisol levels and insulin resist-
ance in the disabled population [75].
However, the role of restricted physical activity on 
insulin resistance and metabolic associated disorders 
should be considered [76–79]. Restricted physical activity 
causes a rapid loss of lean mass, which is associated with 
a decline in basal metabolic rate and increased whole 
body and regional adiposity. The accumulation of ectopic 
adipose tissue may interfere with insulin signaling and 
serve as a source of circulating triglycerides and free-fatty 
acids, which are risk factors for cardiovascular disease. 
The correlation between trygliceride values and free fat 
mass may support the adaptative mechanism. Besides 
restricted physical activity, deterioration in body compo-
sition in NI children and young adults may also be attrib-
uted to reduced human GH, and IGF-1 levels [80–88].
In NI chidren, IR is a crucial factor in increased 
cardio vascular risk, in addition to being a determinant 
factor for stress-induced hyperglycemia, which occurs 
during stressful situations, such as surgery. This in turn 
also increases the infection rates and the length of wound 
healing [89–91]. Pediatric surgeons should also consider 
anthropometric indexes associated with the clinical 
profile and nutritional assessment to monitor surgical 
outcome and avoid complications.
Eventhough children and young patients with NI 
present a variety of motor disorders, orthopedic prob-
lems and other associated conditions that often hinder 
the performance of much-needed exercise, individual 
training standardization is recommended, in order to 
meet the requirements of progressive overload, ameliorat-
ing muscle strength and counteracting metabolic issues. 
Finally, long-term anticonvulsant drugs may be also asso-
ciated with several metabolic abnormalities [92–99] and 
their effects on insulin resistance should be considered.
Survival in severerly disabled patients has improved 
over the past half a century [100–108]. The care and man-
agement of this group with special nutritional needs is of 
particular importance and may improve comorbid meta-
bolic issues. Routine monitoring and follow-up evaluation 
of the nutritional requirements are strongly recommended 
in these medically fragile children and young adults; this 
will improve treatment and care aiming at protecting their 
chances of growth and survival.
Conclusions
Malnutrition and metabolic disorders are relevant in NI 
target. A careful evaluation and monitoring of the nutri-
tional and metabolic state in severely disabled children 
and young adults is recommended to decrease the risk 
of nutrition-related morbidity and mortality. An early 
involvement of a multidisciplinary team of pediatric sur-
geons, pediatricians, clinical nutritionists, nurses, dieti-
cians, physiotherapists, psychologists, speech language 
specialists and social workers is essential to understand-
ing the child’s needs better, to standardize the physiother-
apy program, to prevent adverse outcomes associated with 
feeding difficulties and improve a poor nutritional status.
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